Safety registry for people with high-risk neuroblastoma on dinutuximab beta

This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.

This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.

This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.

This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.

This study creates an international registry linked to a virtual biobank, so researchers can collect and share information and biological samples for patients with specific peripheral neuroblastic tumors. It may help future research and care planning by improving what scientists know about these conditions.

This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.